Actinium Pharmaceuticals, Inc.
(NYSE Amex Equities : ATNM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. -0.24%242.001.3%$852.00m
MRNAModerna, Inc. -1.22%66.340.0%$708.12m
IMMUImmunomedics, Inc. 0.11%85.2611.0%$670.24m
NVAXNovavax, Inc. 4.06%105.6996.5%$629.71m
GILDGilead Sciences, Inc. -1.43%62.191.0%$564.97m
ILMNIllumina, Inc. 2.25%279.153.5%$461.22m
REGNRegeneron Pharmaceuticals, Inc. -0.89%560.142.7%$434.70m
BIIBBiogen, Inc. -0.22%271.591.6%$336.71m
VRTXVertex Pharmaceuticals, Inc. -0.90%261.451.9%$319.01m
ALXNAlexion Pharmaceuticals, Inc. 0.69%113.212.0%$280.91m
SRNESorrento Therapeutics, Inc. -2.93%9.321.5%$261.05m
VXRTVaxart, Inc. 1.11%7.270.0%$206.71m
MNTAMomenta Pharmaceuticals, Inc. 0.15%52.373.0%$205.36m
SGENSeattle Genetics, Inc. -0.74%177.956.0%$200.92m
BMRNBioMarin Pharmaceutical, Inc. -4.30%75.064.3%$189.12m

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY.